Transplant Surgery Clinical Trials
The Division of Transplant Surgery has a thriving research program with a broad portfolio of clinical trials. These are led by Principal Investigators (PI) conducting research to support advances in treatment, supported by a professional staff of trial coordinators and clinical research nurses. Below is a list of active trials including enrollment status and contact information for the study. For an overview of the clinical trial process, see Participating in Clinical Trials.
Islet Cell Transplant
Principal Investigator:
Andrew M. Posselt, M.D., Ph.D.
Andrew M. Posselt, M.D., Ph.D.
Recruiting
Principal Investigator:
Andrew M. Posselt, M.D., Ph.D.
Andrew M. Posselt, M.D., Ph.D.
Recruiting
Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus
Study ID: 39-42C
Principal Investigator:
Peter Stock M.D., Ph.D
Peter Stock M.D., Ph.D
Recruiting
Kidney Transplant
A Dose Escalation and Safety Study of I5NP to Prevent Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation, Part A
Study ID: QRK.006 (Quark)
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Sandy Feng, M.D., Ph.D.
Recruiting
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
Study ID: IM103034
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Principal Investigator:
Andrew M. Posselt, M.D., Ph.D.
Andrew M. Posselt, M.D., Ph.D.
Recruiting
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
Study ID: 0485-CL-U201
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Recruiting
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
Study ID: Benefit
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Recruiting
Principal Investigator:
Stephen J. Tomlanovich, M.D.
Stephen J. Tomlanovich, M.D.
Recruiting
Principal Investigator:
Stephen J. Tomlanovich, M.D.
Stephen J. Tomlanovich, M.D.
Recruiting
Principal Investigator:
Andrew M. Posselt, M.D., Ph.D.
Andrew M. Posselt, M.D., Ph.D.
Recruiting
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
Study ID: A3921050 LTE
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Principal Investigator:
Peter Stock M.D., Ph.D
Peter Stock M.D., Ph.D
Recruiting
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Recruiting
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Study of 2 Dose Levels of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
Study ID: A3921021
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
Study ID: A3921030
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Kidney-Focal Segmental Glomerulosclerosis
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
Study ID: GC1008FSGS00505
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Active, but closed to enrollment
Liver Transplant
Principal Investigator:
Chris E. Freise, M.D.
Chris E. Freise, M.D.
Active, but closed to enrollment
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Sandy Feng, M.D., Ph.D.
Active, but closed to enrollment
Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
Study ID: CRAD001H2304 (RAD)
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Sandy Feng, M.D., Ph.D.
Recruiting
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Study ID: AWISH
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Sandy Feng, M.D., Ph.D.
Recruiting
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
Study ID: CAMPTH
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Sandy Feng, M.D., Ph.D.
Active, but closed to enrollment
Principal Investigator:
Peter Stock M.D., Ph.D
Peter Stock M.D., Ph.D
Recruiting
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
Study ID: COLO400A2426 (REFINE)
Principal Investigator:
John P. Roberts, M.D.
John P. Roberts, M.D.
Active, but closed to enrollment
Pharmacokinetics of LCP-Tacroâ„¢ Once Daily and Prograf ® Twice A Day in Adult De Novo Liver Transplant Patients
Study ID: LifeCycle
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Sandy Feng, M.D., Ph.D.
Active, but closed to enrollment
Principal Investigator:
Flavio Vincenti, M.D.
Flavio Vincenti, M.D.
Recruiting
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Sandy Feng, M.D., Ph.D.
Active, but closed to enrollment
Solid Organ Transplant
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
Study ID: DUSA
Principal Investigator:
Roy Grekin, M.D.
Roy Grekin, M.D.
Recruiting